Ocugen reported positive preliminary 12-month data from its Phase 2 ArMaDa clinical trial of OCU410 (AAV5-RORA), a modifier gene therapy being developed for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD). Early results in approximately half of participants evaluated at 12 months showed a 46% reduction in lesion growth versus control, with the medium-dose cohort achieving a 54% reduction and the high-dose cohort a 36% reduction, all compared with untreated control subjects. A 50% responder rate was observed for patients achieving more than half reduction in lesion size versus control. In a subgroup of subjects with larger baseline lesions (≥7.5 mm²), lesion growth was reduced by 57% compared with control.

Safety and structural outcomes

Across the Phase 1 and Phase 2 ArMaDa studies, no OCU410-related serious adverse events have been reported, and there have been no cases of key ocular complications such as endophthalmitis or retinal detachment. In Phase 1 evaluable eyes, OCU410 treatment slowed ellipsoid zone (EZ) loss by about 60% versus untreated fellow eyes at 12 months, and preserved photoreceptor and retinal pigment epithelium structure compared with fellow eyes, suggesting a potential protective effect on retinal integrity.

Ocugen’s leadership said the Phase 2 findings support the potential of its multi-pathway RORA approach, and the company plans to report full Phase 2 data later this quarter and to initiate a Phase 3 trial in 2026, advancing OCU410 toward potential registration.

OCU410 and the competitive landscape

GA is a leading cause of vision loss in patients with dAMD, affecting millions in the US and Europe and representing a substantial unmet medical need with limited approved treatment options. Two drugs were approved for GA in 2023 – Syfovre (pegcetacoplan) from Apellis Pharmaceuticals, and Izervay (avacincaptad pegol) from Iveric Bio (now Astellas), both complement inhibitors. However, these require frequent intravitreal injections and do not address the multifactorial disease pathways implicated in GA.

OCU410 is an investigational gene therapy that utilizes an adeno-associated virus serotype 5 (AAV5) vector to deliver the human RORA (retinoic acid receptor-related orphan receptor alpha) gene directly to the retina. The therapy is designed as a one-time, subretinal injection aiming to restore retinal homeostasis by modulating multiple disease pathways: lipid metabolism, oxidative stress, inflammation, and complement activation. This multi-modal approach distinguishes OCU410 both from Syfovre and Apelis, as well as competing clinical-stage investigational candidates, which typically target only a single pathway (complement inhibition). Other gene therapies in development for GA include:

• GT005 from Gyroscope Therapeutics, now part of the Novartis portfolio, which uses an AAV2 vector to deliver complement factor I (CFI);
• JNJ-1887 (formerly HMR59), developed by Janssen/Johnson & Johnson, employing an AAV2 vector expressing soluble CD59 to inhibit formation of the membrane attack complex, a terminal effector of complement activation, currently Phase 2b stage;
• CTx001, from Complement Therapeutics, an AAV-based gene therapy encoding a truncated complement receptor 1 (CR1) designed to modulate the complement cascade. The molecule is under Phase 1/2 study;
• Lastly, SAR446597 from Sanofi is a one-time intravitreal gene therapy aimed at complement modulation with Fast Track designation and an early Phase 1/2 program planned.